RESCULA
LOE Approachingunoprostone isopropyl
NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Aug 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RESCULA (unoprostone isopropyl) is a prostaglandin analogue ophthalmic solution approved in 2000 for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is administered as eye drops and works by increasing uveoscleral outflow of aqueous humor.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling potential team reductions or transition planning as market exclusivity erodes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RESCULA offers limited new career growth opportunities given zero linked job openings and approaching LOE status. Positions in this product are best suited for professionals seeking mature market management experience or defensive strategy work ahead of generic entry.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.